Parabilis Medicines, Inc. (PBLS) cash on hand
Only 2 fiscal years of cash are on record here for Parabilis Medicines, Inc. (PBLS); a history needs at least 3. Figures as of 17 Nov 2026, 21:39 UTC, from Yahoo Finance.
Key facts
- Cash, fiscal 2025
- $27.71M
- Change on fiscal 2024
- −68.5%
- Fiscal years on record
- 22024–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Not enough data
A history of cash needs at least 3 fiscal years; 2 are on record here for Parabilis Medicines, Inc.. Nothing is estimated to fill the gap. What is on record is in the table below.
Parabilis Medicines, Inc. cash on hand, year by year
| Fiscal year | Cash | Change | Year ended |
|---|---|---|---|
| 2025 | $27.71M | 68.5% down | |
| 2024 | $87.98M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
How to read it
Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.
Parabilis Medicines, Inc., figure by figure
- Parabilis Medicines, Inc. market cap
- Parabilis Medicines, Inc. revenue
- Parabilis Medicines, Inc. earnings
- Parabilis Medicines, Inc. earnings per share (EPS)
- Parabilis Medicines, Inc. P/E ratio
- Parabilis Medicines, Inc. P/S ratio
- Parabilis Medicines, Inc. P/B ratio
- Parabilis Medicines, Inc. free cash flow
- Parabilis Medicines, Inc. operating margin
- Parabilis Medicines, Inc. dividend
- Parabilis Medicines, Inc. shares outstanding
- Parabilis Medicines, Inc. total debt
- Parabilis Medicines, Inc. total assets
- Parabilis Medicines, Inc. return on equity (ROE)
- Parabilis Medicines, Inc. return on invested capital (ROIC)
Parabilis Medicines, Inc. (PBLS) overview: price, valuation and scorecard
Parabilis Medicines, Inc. cash on hand: questions and answers
How is Parabilis Medicines, Inc.'s cash calculated?
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
Fiscal years are named for the calendar year they end in.
Learn: cash on hand
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Parabilis Medicines, Inc. (PBLS) cash on hand”, data as of 17 November 2026. https://funkfolio.com/stock/PBLS/cash
Underlying data: Yahoo Finance.